果糖嗪及脱氧果糖嗪首批国家对照品的研制

doi:10.19803/j.1672-8629.20220223

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (3): 282-285.
DOI: 10.19803/j.1672-8629.20220223

果糖嗪及脱氧果糖嗪首批国家对照品的研制

刘博^1,2, 郭云霄³, 张佟^1,2, 黄露^1,2, 贺兰英^1,2, 范慧红^1,2,*

¹中国食品药品检定研究院化学药品检定所,北京 102629;
²国家药品监督管理局化学药品质量研究与评价重点实验室,北京 102629;
³中国药科大学药学院,江苏南京 210009

收稿日期:2022-05-07 出版日期:2023-03-15 发布日期:2023-03-17
通讯作者: ^* 范慧红,女,博士,研究员,生化药品质量控制。E-mail: shenghuayaoshi@126.com
作者简介:刘博,男,博士,副研究员,生化药品质量控制。
基金资助:
北京市自然科学基金资助项目（7194337）; 中国食品药品检定研究院化学药品检定所重点实验室课题（1030050090142）

A national reference standard for fructosazine and deoxyfructosazine

LIU Bo^1,2, GUO Yunxiao³, ZHANG Tong^1,2, HUANG Lu^1,2, HE Lanying^1,2, FAN Huihong^1,2,*

¹Institute for Chemical Drug Control, National Institutes for Food and Drug Control, Beijing 102629, China;
²NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing 102629, China;
³School of Pharmacy, China Pharmaceutical University, Nanjing Jiangsu 210009, China

Received:2022-05-07 Online:2023-03-15 Published:2023-03-17

摘要/Abstract

摘要： 目的为有效控制氨基葡萄糖类药物的产品质量,研制供氨基葡萄糖类药物原料及制剂有关物质检查用的果糖嗪及脱氧果糖嗪国家对照品。方法采用核磁共振、红外光谱、质谱手段进行结构鉴定,同时通过核磁共振氢谱与圆二色谱相结合的方式对2种待标品的绝对构型进行确认;采用2种高效液相色谱法进行纯度分析;分别利用多种分析方法对2种待标品的无机杂质、理化特性、均匀性与稳定性进行考察,采用质量平衡法进行含量赋值,并采用核磁共振定量法对赋值结果进行验证。结果 2种杂质对照品结构准确,果糖嗪含量为98.0%,脱氧果糖嗪含量为95.1%。结论依据本研究所述方法研制的果糖嗪及脱氧果糖嗪首批国家对照品,可满足盐酸氨基葡萄糖、硫酸氨基葡萄糖原料及其制剂的质控需要。

关键词: 果糖嗪, 脱氧果糖嗪, 氨基葡萄糖, 研制对照品

Abstract: Objective To establish new national reference standards for fructosazine and deoxyfructosazine used for impurity determination of raw materials or preparations of glucosamine in order to ensure the quality of products of glucosamine. Methods UV, HRMS, ¹HNMR, ¹³CNMR, 2D NMR and CD were used to confirm the structure while the content of the product was calculated using the mass balance method before being verified by the QNMR method. Results The structure of this product was identified and the contents of fructosazine and deoxyfructosazine were assigned as 98.0% and 95.1% respectively. Conclusion Fructosazine and deoxyfructosazine have been established as national reference standards for the first time, which can be applied to quality control of glucosamine and related products.

Key words: fructosazine, deoxyfructosazine, glucosamine, establishing national reference standards

中图分类号:

R927

刘博, 郭云霄, 张佟, 黄露, 贺兰英, 范慧红. 果糖嗪及脱氧果糖嗪首批国家对照品的研制[J]. 中国药物警戒, 2023, 20(3): 282-285.

LIU Bo, GUO Yunxiao, ZHANG Tong, HUANG Lu, HE Lanying, FAN Huihong. A national reference standard for fructosazine and deoxyfructosazine[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 282-285.

参考文献

[1] TARUC RL, LYNCH SA.Diagnosis and treatment of osteoarthritis[J]. Primary Care, 2013, 40(4): 821-836.
[2] SACITHARAN PK.Ageing and osteoarthritis[J]. Subcell Biochem, 2019, 91:123-159.
[3] TANG X, WANG S, ZHAN S, et al.The prevalence of symptomatic knee osteoarthritis in China: results from the china health and retirement longitudinal study[J]. Arthritis Rheumatol, 2016, 68(3): 648-653.
[4] LESPASIO MJ, PIUZZI NS, HUSNI ME, et al.Knee osteoarthritis: a primer[J]. Permanente Journal, 2017, 21: 16-183.
[5] HERMANN W, LAMBOVA S, MULLER-LADNER U.Current treatment options for osteoarthritis[J]. Current Rheumatology Reviews, 2018, 14(2): 108-116.
[6] EBELL MH.Osteoarthritis: rapid evidence review[J]. American Family Physician, 2018, 97(8): 523-526.
[7] LOO S, JYET Q, WONG N.Advantages and challenges of stem cell therapy for osteoarthritis (Review)[J]. Biomedical Reports, 2021, 15(2): 67-78.
[8] JI LW, FU DX.Pharmacological effects and safety of amino glucose[J]. China Pharmaceutical Journal(中国药学杂志), 2007, 42(19): 1513-1516.
[9] XIAO YL, LI LP, CHENG YN, et al.Progress in the study of pharmacology and application of chondroitin sulfate[J]. China Pharmaceutical Journal(中国药学杂志), 2014, 49(13): 1093-1098.
[10] CHEN SY, HU N, JIA YB, et al.Expert consensus on clinical drug treatment of osteoarthritis[J]. Chinese Journal of the Frontiers of Medical Science(中国医学前沿杂志), 2021, 13(7): 32-43.
[11] LI CH, HUANG H, WU HL, et al.Efficacy of diclofenac sodium patch combined with glucosamine sulfate in the treatment of primary osteoarthritis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(11): 641-646.
[12] ZHANG WB.Expert consensus on glucosamine in the treatment of osteoarthritis[J]. Chinese Journal of Surgery(中华外科杂志), 2008, 46(18): 1437-1438.
[13] WAND D, LIU JP, TANG FX.Effect of glucosamine sulfate combined with ultra-short wave on knee osteoarthritis[J]. Chinese Journal of Practical Medicine(中国实用医刊), 2021, 48(20): 69-72.
[14] The United States Pharmacopeial Convention. U.S. Pharmacopeia National Formulary (USP43-NF38) Volume 2[M]. Baltimore: United Book Press, 2021: 7698-7698.
[15] Convention On the Elaboration of a European Pharmacopoeia. European Pharmacopoeia(EP 10.0)[M]. 2019. 2757-2758.
[16] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China (中华人民共和国药典)[M]. Beijing: China Medical Science Press, 2020.
[17] HAN YZ.Certification of certified reference materials[J]. Chemical Analysis and Meterage(化学分析计量), 2001, 10(5): 38-40.

果糖嗪及脱氧果糖嗪首批国家对照品的研制

A national reference standard for fructosazine and deoxyfructosazine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	黎春辉,黄浩,吴红莉,赵祥,边武. 双氯芬酸钠贴片联合硫酸氨基葡萄糖治疗骨性关节炎的疗效观察[J]. 中国药物警戒, 2013, 10(11): 641-642.
[2]	黄鹏, 张秀真, 田德祥, 冯传平. 离子色谱法测定氨基葡萄糖枸橼酸钙分散片的含量[J]. 中国药物警戒, 2010, 7(8): 449-450.